Overview
SMMT market data
Price History
SMMT price chart · 1M
- O
- 14.36
- H
- 14.61
- L
- 13.92
- C
- 14.32
- Vol
- 289,061.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $14.36
- Previous Close
- $14.21
- Day High
- $14.61
- Day Low
- $13.92
- 52 Week High
- $22.36
- 52 Week Low
- $12.08
- 7 Day Return
- +15.30%
- 30 Day Return
- +14.10%
- 90 Day Return
- -18.31%
- 1 Year Return
- -31.20%
- Daily Notional Volume
- $4.1M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.31 Diluted earnings per share over the trailing twelve months.
- Beta
- -1.61 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -9,027.1% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $12.07 – $30.05 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $11.3B · P/B 19.76 · P/S 11,808.36.
Company News
SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer StudyZacks Investment Research · Aug 27, 2026, 6:15 PM
Summit Therapeutics Partner Highlights Positive Interim Data Milestone for Lead Cancer TherapyBenzinga · Aug 26, 2026, 5:46 PM
Nasdaq 100 Falls as Hot PCE Inflation Stirs Rate-Hike Bets: Stock Market TodayBenzinga · Aug 26, 2026, 4:58 PM
Abercrombie & Fitch Posts Upbeat Q2 Results, Joins Semtech, Summit Therapeutics And Other Big Stocks Moving Higher On WednesdayBenzinga · Aug 26, 2026, 2:16 PM
8-K filing — Summit Therapeutics Inc. (SMMT)SEC EDGAR · Aug 26, 2026, 1:17 PM
Summit Therapeutics shares are trading higher after the company announced topline results from the randomized Phase III HARMONi-GI1 study met the key secondary endpoints of progression-free survival and objective response rate.Benzinga · Aug 26, 2026, 11:43 AM
HC Wainwright & Co. Reiterates Neutral on Summit Therapeuticsto NeutralBenzinga · Aug 26, 2026, 10:55 AM
Summit Therapeutics' Partner Akeso Announces Topline Results From The Randomized Phase III HARMONi-GI1 Study Evaluating Ivonescimab Plus Chemotherapy Compared With Durvalumab Plus Chemotherapy As A First-line Treatment For Patients With Advanced Biliary Tract Cancer; Study Meets Key Secondary Endpoints Of PFS And ORRBenzinga · Aug 25, 2026, 10:05 PM
Summit Therapeutics Says Ivonescimab Combination Extends Progression-Free Survival in Lung Cancer PatientsBenzinga · Aug 25, 2026, 4:33 PM
Summit Therapeutics shares are trading higher after the company announced the publication of primary analysis results from the global Phase III HARMONi clinical trial in The Lancet Oncology. Bernstein upgraded the stock from Underperform to Market Perform and raised its price target from $9.8 to $11.9.Benzinga · Aug 25, 2026, 2:09 PM